US5059714A
(en)
|
1988-02-25 |
1991-10-22 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US5021456A
(en)
|
1988-02-25 |
1991-06-04 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US5182297A
(en)
|
1988-02-25 |
1993-01-26 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US4965288A
(en)
|
1988-02-25 |
1990-10-23 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US4943593A
(en)
|
1988-02-25 |
1990-07-24 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US5252608A
(en)
|
1988-02-25 |
1993-10-12 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US5120764A
(en)
|
1988-11-01 |
1992-06-09 |
Merrell Dow Pharmaceuticals Inc. |
Inhibitors of lysyl oxidase
|
US4997854A
(en)
|
1989-08-25 |
1991-03-05 |
Trustees Of Boston University |
Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
|
US6319494B1
(en)
|
1990-12-14 |
2001-11-20 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
WO1997031910A1
(en)
|
1996-02-28 |
1997-09-04 |
Merck & Co., Inc. |
Fibrinogen receptor antagonists
|
US6297239B1
(en)
|
1997-10-08 |
2001-10-02 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
JP2001002661A
(ja)
|
1999-06-22 |
2001-01-09 |
Ricoh Co Ltd |
ニトリル化合物及びその製造方法
|
US6465648B1
(en)
|
1999-06-22 |
2002-10-15 |
Ricoh Company, Ltd. |
Reaction product, process of producing same, electrophotographic photoconductor using same, electrophotographic apparatus having the photoconductor, and process cartridge for electrophotographic apparatus
|
US6632815B2
(en)
|
1999-09-17 |
2003-10-14 |
Millennium Pharmaceuticals, Inc. |
Inhibitors of factor Xa
|
BR0014078A
(pt)
|
1999-09-17 |
2002-12-31 |
Millennium Pharm Inc |
Inibidores de fator xa
|
AU2001234689A1
(en)
|
2000-02-01 |
2001-08-14 |
Cor Therapeutics, Inc. |
Bivalent phenylene inhibitors of factor xa
|
JP2001335476A
(ja)
|
2000-05-29 |
2001-12-04 |
Shionogi & Co Ltd |
三環化合物の新規用途
|
JP2004501913A
(ja)
|
2000-06-23 |
2004-01-22 |
ブリストル−マイヤーズ スクイブ ファーマ カンパニー |
ヘテロアリール−フェニル置換Xa因子阻害剤
|
WO2002020436A2
(en)
|
2000-09-05 |
2002-03-14 |
Neogenesis Pharmaceuticals, Inc. |
Methods for forming combinatorial libraries combining amide bond formation with epoxide opening
|
WO2002051775A2
(en)
|
2000-12-22 |
2002-07-04 |
Neogenesis Pharmaceuticals, Inc. |
Methods for forming combinatorial libraries using reductive amination
|
DE10104279A1
(de)
|
2001-01-31 |
2002-08-01 |
Heinz Langhals |
Kompetitive Prionen-Reagenzien und ihre Anwendung in Diagnostik und Therapie
|
FR2828206B1
(fr)
|
2001-08-03 |
2004-09-24 |
Centre Nat Rech Scient |
Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
|
EP1426046A4
(en)
|
2001-09-14 |
2005-11-02 |
Shionogi & Co |
NEW USE OF TRICYCLIC COMPOUNDS
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
AU2003302925A1
(en)
|
2002-12-11 |
2004-06-30 |
Eli Lilly And Company |
Novel mch receptor antagonists
|
WO2004054582A1
(en)
|
2002-12-13 |
2004-07-01 |
Neurogen Corporation |
Combination therapy for the treatment of pain
|
JP2006521357A
(ja)
*
|
2003-03-24 |
2006-09-21 |
メルク エンド カムパニー インコーポレーテッド |
ナトリウムチャンネル遮断薬としてのビアリール置換6員複素環化合物
|
US7244763B2
(en)
|
2003-04-17 |
2007-07-17 |
Warner Lambert Company Llc |
Compounds that modulate PPAR activity and methods of preparation
|
US7405295B2
(en)
|
2003-06-04 |
2008-07-29 |
Cgi Pharmaceuticals, Inc. |
Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
|
GB0325956D0
(en)
|
2003-11-06 |
2003-12-10 |
Addex Pharmaceuticals Sa |
Novel compounds
|
WO2005051890A1
(en)
|
2003-11-19 |
2005-06-09 |
Smithkline Beecham Corporation |
Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
|
US7432278B2
(en)
|
2004-03-08 |
2008-10-07 |
The University Of North Carolina At Chapel Hill |
Dicationic imidazo[1,2-a]pyridines and 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridines as antiprotozoal agents
|
AU2005231332A1
(en)
|
2004-03-29 |
2005-10-20 |
Merck & Co., Inc. |
Biaryl substituted pyrazinones as sodium channel blockers
|
WO2005095338A1
(ja)
|
2004-03-30 |
2005-10-13 |
Takeda Pharmaceutical Company Limited |
アルコキシフェニルプロパン酸誘導体
|
CN101031569B
(zh)
|
2004-05-13 |
2011-06-22 |
艾科斯有限公司 |
作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮
|
US20060019967A1
(en)
|
2004-07-21 |
2006-01-26 |
Su-Ying Wu |
SARS CoV main protease inhibitors
|
JP2007284350A
(ja)
|
2004-07-27 |
2007-11-01 |
Takeda Chem Ind Ltd |
糖尿病治療剤
|
EP1810677A1
(en)
|
2004-10-08 |
2007-07-25 |
Takeda Pharmaceutical Company Limited |
Receptor function regulating agent
|
WO2006040646A1
(en)
|
2004-10-14 |
2006-04-20 |
Pfizer, Inc. |
Benzimidazole or indole amides as inhibitors of pin1
|
JP5785354B2
(ja)
|
2004-11-03 |
2015-09-30 |
アリーナ ファーマシューティカルズ, インコーポレイテッド |
インスリン関連障害の処置のためのgpr41およびその調節因子
|
US20080090865A1
(en)
|
2005-01-28 |
2008-04-17 |
Min Ge |
Antidiabetic Bicyclic Compounds
|
JP2008528628A
(ja)
|
2005-01-31 |
2008-07-31 |
メルク エンド カムパニー インコーポレーテッド |
抗糖尿病性二環式化合物
|
AU2006216997A1
(en)
|
2005-02-11 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Substituted imidazoquinolines and imidazonaphthyridines
|
US20090142345A1
(en)
|
2005-03-15 |
2009-06-04 |
Takeda Pharmaceutical Company Limited |
Prophylactic/therapeutic agent for cancer
|
PL2439273T3
(pl)
|
2005-05-09 |
2019-08-30 |
Ono Pharmaceutical Co., Ltd. |
Ludzkie przeciwciała monoklonalne przeciwko białku programowanej śmierci komórki 1(pd-1) oraz metody leczenia nowotworów z wykorzystaniem przeciwciał anty-pd-1 samodzielnie lub w połączeniu z innymi immunoterapeutykami
|
GB0510141D0
(en)
|
2005-05-18 |
2005-06-22 |
Addex Pharmaceuticals Sa |
Novel compounds B3
|
US7465804B2
(en)
|
2005-05-20 |
2008-12-16 |
Amgen Inc. |
Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
|
RS54271B1
(en)
|
2005-07-01 |
2016-02-29 |
E. R. Squibb & Sons, L.L.C. |
HUMAN MONOCLONIC ANTIBODIES FOR LIGAND PROGRAMMED DEATH 1 (PD-L1)
|
US8153694B2
(en)
|
2005-07-29 |
2012-04-10 |
Takeda Pharmaceutical Company Limited |
Cyclopropanecarboxylic acid compound
|
TWI404537B
(zh)
|
2005-08-19 |
2013-08-11 |
Array Biopharma Inc |
作為類鐸受體(toll-like receptor)調節劑之8-經取代苯并氮雜呯
|
TWI382019B
(zh)
|
2005-08-19 |
2013-01-11 |
Array Biopharma Inc |
作為類鐸受體(toll-like receptor)調節劑之胺基二氮雜呯
|
AU2006291234A1
(en)
|
2005-09-14 |
2007-03-22 |
Amgen Inc. |
Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
|
US7935727B2
(en)
|
2005-10-19 |
2011-05-03 |
Merck Sharp & Dohme Corp. |
CETP inhibitors
|
WO2007049050A2
(en)
|
2005-10-27 |
2007-05-03 |
Heptahelix Ab |
Modulators of gpr40 for the treatment of diabetes
|
WO2007052466A1
(ja)
|
2005-11-04 |
2007-05-10 |
Eisai R & D Management Co., Ltd. |
Gpr40とホスホリパーゼとを用いる疾患に有用な物質のスクリーニング方法
|
US20100249175A1
(en)
|
2005-12-02 |
2010-09-30 |
Wilson W David |
Dicationic compounds which selectively recognize G-quadruplex DNA
|
DK1976828T3
(en)
|
2005-12-29 |
2017-03-06 |
Celtaxsys Inc |
DIAMINE DERIVATIVES AS INhibitors of Leukotriene A4 HYDROLASE
|
EA200801865A1
(ru)
|
2006-02-22 |
2009-02-27 |
Филоджен Спа |
Опухолевые маркеры сосудов
|
AU2007225208A1
(en)
|
2006-03-14 |
2007-09-20 |
Amgen Inc. |
Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
|
DE102006012251A1
(de)
|
2006-03-15 |
2007-11-08 |
Grünenthal GmbH |
Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln
|
EP2389948A1
(en)
|
2006-03-23 |
2011-11-30 |
Novartis AG |
Anti-tumor cell antigen antibody therapeutics
|
ES2649564T3
(es)
|
2006-03-31 |
2018-01-12 |
Novartis Ag |
Inhibidores de DGAT
|
TW200815377A
(en)
|
2006-04-24 |
2008-04-01 |
Astellas Pharma Inc |
Oxadiazolidinedione compound
|
EP1849781A1
(en)
|
2006-04-28 |
2007-10-31 |
Laboratorios del Dr. Esteve S.A. |
Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
|
AU2007251282A1
(en)
|
2006-05-09 |
2007-11-22 |
Pfizer Products Inc. |
Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
|
DE102006021874B4
(de)
|
2006-05-11 |
2008-03-27 |
Sanofi-Aventis |
4,5-Diphenyl-pyrimidinyl-amino substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE502007001453D1
(de)
|
2006-05-11 |
2009-10-15 |
Sanofi Aventis |
4,5-diphenyl-pyrimidinyl substituierte carbonsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
|
DE102006021872B4
(de)
|
2006-05-11 |
2008-04-17 |
Sanofi-Aventis |
4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE102006021878A1
(de)
|
2006-05-11 |
2007-11-15 |
Sanofi-Aventis |
Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
WO2007136572A2
(en)
|
2006-05-15 |
2007-11-29 |
Merck & Co., Inc. |
Antidiabetic bicyclic compounds
|
PE20080993A1
(es)
|
2006-06-27 |
2008-10-06 |
Takeda Pharmaceutical |
Compuestos ciclicos fusionados como moduladores del receptor gpr40
|
US20100056495A1
(en)
|
2006-07-24 |
2010-03-04 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
US7759495B2
(en)
|
2006-08-11 |
2010-07-20 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2064193A1
(en)
|
2006-09-07 |
2009-06-03 |
Amgen, Inc |
Heterocyclic gpr40 modulators
|
WO2008037266A1
(en)
|
2006-09-25 |
2008-04-03 |
Universite Libre De Bruxelles |
Inhibitors of conventional protein kinase c isozymes and use thereof for treating inflammatory diseases
|
US8338394B2
(en)
|
2006-10-12 |
2012-12-25 |
Case Western Reserve University |
Methods for treating metabolic diseases
|
JP2010508268A
(ja)
|
2006-10-31 |
2010-03-18 |
メルク エンド カムパニー インコーポレーテッド |
抗糖尿病二環式化合物
|
WO2008054674A2
(en)
|
2006-10-31 |
2008-05-08 |
Merck & Co., Inc. |
Antidiabetic bicyclic compounds
|
US7750048B2
(en)
|
2006-11-15 |
2010-07-06 |
Janssen Pharmaceutica Nv |
GPR40 agonists
|
WO2008065409A2
(en)
|
2006-12-01 |
2008-06-05 |
Betagenon Ab |
Combination for use in the treatment of cancer, comprising tamoxifen or an aromatase inhibitor
|
TW200838526A
(en)
|
2006-12-01 |
2008-10-01 |
Astellas Pharma Inc |
Carboxylic acid derivatives
|
JP2010511635A
(ja)
|
2006-12-04 |
2010-04-15 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Hiv複製の阻害剤
|
CA2671315A1
(en)
|
2006-12-11 |
2008-06-19 |
Novartis Ag |
Method of preventing or treating myocardial ischemia by inhibiting dgat1 enzyme with a dgat1 inhibitor
|
EP2125781A2
(en)
|
2006-12-20 |
2009-12-02 |
Amgen Inc. |
Substituted heterocycles and methods of use
|
CA2673038C
(en)
|
2006-12-22 |
2015-12-15 |
Incyte Corporation |
Substituted tricyclic heteroaryl compounds as janus kinase inhibitors
|
NZ577348A
(en)
|
2006-12-28 |
2012-04-27 |
Abbott Lab |
Inhibitors of poly(adp-ribose)polymerase
|
WO2008090327A1
(en)
|
2007-01-22 |
2008-07-31 |
Betagenon Ab |
New combination for use in the treatment of cancer
|
WO2008090356A1
(en)
|
2007-01-25 |
2008-07-31 |
Betagenon Ab |
Thiazolidinone derivatives useful in the treatment of cancer and disorders caused by excess adiposity
|
WO2008106202A1
(en)
|
2007-02-27 |
2008-09-04 |
Housey Gerard M |
Theramutein modulators
|
PT2152701E
(pt)
|
2007-03-12 |
2016-01-27 |
Ym Biosciences Australia Pty |
Compostos de fenil amino pirimidina e suas utilizações
|
WO2008130514A1
(en)
|
2007-04-16 |
2008-10-30 |
Amgen Inc. |
Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators
|
US8318781B2
(en)
|
2007-04-26 |
2012-11-27 |
Japan Science And Technology Agency |
G-protein-conjugated receptor agonist
|
WO2008147852A1
(en)
|
2007-05-22 |
2008-12-04 |
Taigen Biotechnology Co., Ltd. |
Kinesin inhibitors
|
US20100203012A1
(en)
|
2007-05-30 |
2010-08-12 |
Aegera Therapeutics, Inc. |
Iap bir domain binding compounds
|
EP2002838A1
(de)
|
2007-06-13 |
2008-12-17 |
Bayer Schering Pharma AG |
Verwendung von Aryl/Hetarylamid-Derivaten als Modulatoren des EP2-Rezeptors
|
WO2008156656A2
(en)
|
2007-06-13 |
2008-12-24 |
State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University |
Method for making biaryl compounds, compounds made by the method, and method for their use
|
KR101561710B1
(ko)
|
2007-06-29 |
2015-10-19 |
길리애드 사이언시즈, 인코포레이티드 |
퓨린 유도체 및 그것의 톨 유사 수용체 7의 조절 인자로서 용도
|
HUE025283T2
(en)
|
2007-08-02 |
2016-03-29 |
Gilead Biologics Inc |
LOX and LOX2 inhibitors and their use
|
US7928140B2
(en)
|
2007-08-02 |
2011-04-19 |
Amgen Inc. |
Benzothiazole PI3 kinase modulators for cancer treatment
|
TWI649303B
(zh)
|
2007-08-17 |
2019-02-01 |
杜邦股份有限公司 |
製備4-乙醯基-n-〔2-側氧基-2-〔(2,2,2-三氟乙基)胺基〕乙基〕-1-萘甲醯胺之化合物及方法
|
WO2009038204A1
(ja)
|
2007-09-17 |
2009-03-26 |
Pharma Frontier Co., Ltd. |
新規長鎖脂肪酸誘導体化合物及びそれら化合物を有効成分とするgタンパク質共役型レセプター作動剤
|
EP2203415B1
(de)
|
2007-09-21 |
2016-10-26 |
Sanofi |
(cyclopropyl-phenyl)-phenyl-oxalamide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
|
WO2009039943A1
(de)
|
2007-09-21 |
2009-04-02 |
Sanofi-Aventis |
(carboxylalkylen-phenyl)-phenyl-oxalamide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
|
WO2009047798A2
(en)
|
2007-10-08 |
2009-04-16 |
Advinus Therapeutics Private Limited |
Acetamide derivatives as glucokinase activators, their process and medicinal applications
|
AU2008311355B2
(en)
|
2007-10-10 |
2012-01-19 |
Amgen Inc. |
Substituted biphenyl GPR40 modulators
|
JP2011016722A
(ja)
|
2007-10-23 |
2011-01-27 |
Astellas Pharma Inc |
チアゾリジンジオン化合物
|
CN101835764B
(zh)
|
2007-10-24 |
2012-09-19 |
安斯泰来制药有限公司 |
唑甲酰胺化合物或其盐
|
ME02338B
(me)
|
2007-10-26 |
2013-02-28 |
Japan Tobacco Inc |
Spiro-ciklično jedinjenje i njegova upotreba u medicinske svrhe
|
AU2008319418B2
(en)
|
2007-10-29 |
2013-08-15 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
US8147818B2
(en)
|
2008-02-13 |
2012-04-03 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7704992B2
(en)
|
2008-02-13 |
2010-04-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
MX2010009654A
(es)
|
2008-03-06 |
2010-09-28 |
Amgen Inc |
Derivados de acido carboxilico de conformacion restringida utiles para tratar trastornos metabolicos.
|
WO2009112445A1
(en)
|
2008-03-10 |
2009-09-17 |
Novartis Ag |
Method of increasing cellular phosphatidyl choline by dgat1 inhibition
|
ES2524266T3
(es)
|
2008-07-08 |
2014-12-04 |
Incyte Corporation |
1,2,5-Oxadiazoles como inhibidores de la indoleamina 2,3-dioxigenasa
|
PL2604693T3
(pl)
|
2008-07-21 |
2016-09-30 |
|
Jednołańcuchowe cząsteczki TNFSF
|
EP2313360B1
(en)
|
2008-07-28 |
2012-09-05 |
Syddansk Universitet |
Compounds for the treatment of metabolic diseases
|
DK2313111T3
(da)
|
2008-08-01 |
2013-12-02 |
Ventirx Pharmaceuticals Inc |
Toll-lignende receptoragonistformuleringer og anvendelse deraf
|
WO2010019702A2
(en)
|
2008-08-12 |
2010-02-18 |
Oncomed Pharmaceuticals, Inc. |
Ddr1-binding agents and methods of use thereof
|
DE102008037790A1
(de)
|
2008-08-14 |
2010-02-18 |
Merck Patent Gmbh |
Bicyclische Triazolderivate
|
CA2739303A1
(en)
|
2008-10-01 |
2010-04-08 |
Synta Pharmaceuticals Corp. |
Compounds for inflammation and immune-related uses
|
EP2358656B1
(en)
|
2008-10-15 |
2014-01-01 |
Amgen, Inc |
Spirocyclic gpr40 modulators
|
WO2010066682A1
(en)
|
2008-12-08 |
2010-06-17 |
Euroscreen S.A. |
Compounds, pharmaceutical composition and methods for use in treating metabolic disorders
|
US8450321B2
(en)
|
2008-12-08 |
2013-05-28 |
Gilead Connecticut, Inc. |
6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
|
ES2623794T3
(es)
|
2008-12-09 |
2017-07-12 |
Gilead Sciences, Inc. |
Intermedios para la preparación de moduladores de receptores tipo toll
|
EP2367824B1
(en)
|
2008-12-23 |
2016-03-23 |
AbbVie Inc. |
Anti-viral derivatives of pyrimidine
|
WO2010082563A1
(ja)
|
2009-01-19 |
2010-07-22 |
第一三共株式会社 |
ヘテロ原子を有する環状化合物
|
JP2012515779A
(ja)
|
2009-01-23 |
2012-07-12 |
シェーリング コーポレイション |
ペンタフルオロスルホラン含有抗糖尿病化合物
|
US20110312967A1
(en)
|
2009-01-23 |
2011-12-22 |
Schering Corporation |
Bridged and fused antidiabetic compounds
|
EP2389226B1
(en)
|
2009-01-23 |
2013-11-20 |
Merck Sharp & Dohme Corp. |
Bridged and fused heterocyclic antidiabetic compounds
|
EP2393810A1
(en)
|
2009-02-05 |
2011-12-14 |
Schering Corporation |
Phthalazine-containing antidiabetic compounds
|
WO2010091413A1
(en)
|
2009-02-09 |
2010-08-12 |
Enanta Pharmaceuticals, Inc. |
Linked dibenzimidazole derivatives
|
WO2010096462A1
(en)
|
2009-02-17 |
2010-08-26 |
Enanta Pharmaceuticals, Inc |
Linked diimidazole derivatives
|
CA2753382C
(en)
|
2009-02-27 |
2014-12-23 |
Enanta Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
CN102427726B
(zh)
|
2009-03-27 |
2014-10-08 |
普雷西迪奥制药公司 |
丙型肝炎的稠环抑制剂
|
JP2012136438A
(ja)
|
2009-04-22 |
2012-07-19 |
Astellas Pharma Inc |
テトラゾール化合物
|
WO2010123016A1
(ja)
|
2009-04-22 |
2010-10-28 |
アステラス製薬株式会社 |
カルボン酸化合物
|
JP5582662B2
(ja)
|
2009-05-13 |
2014-09-03 |
ギリアード サイエンシーズ, インコーポレイテッド |
抗ウイルス化合物
|
EP2440541A1
(en)
|
2009-06-09 |
2012-04-18 |
Takeda Pharmaceutical Company Limited |
Novel fused cyclic compound and use thereof
|
CN102333772B
(zh)
|
2009-06-11 |
2013-12-11 |
雅培制药有限公司 |
抗病毒化合物
|
TWI625121B
(zh)
|
2009-07-13 |
2018-06-01 |
基利科學股份有限公司 |
調節細胞凋亡信號之激酶的抑制劑
|
EP2467377B1
(en)
|
2009-08-18 |
2016-12-28 |
Ventirx Pharmaceuticals, Inc. |
Substituted benzoazepines as toll-like receptor modulators
|
PL2467380T3
(pl)
|
2009-08-18 |
2017-09-29 |
Ventirx Pharmaceuticals, Inc. |
Podstawione benzoazepiny jako modulatory receptora typu Toll
|
GB0914856D0
(en)
|
2009-08-25 |
2009-09-30 |
Ark Therapeutics Ltd |
Compounds
|
WO2011031934A1
(en)
|
2009-09-11 |
2011-03-17 |
Enanta Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
WO2011031965A1
(en)
|
2009-09-14 |
2011-03-17 |
Gilead Sciences, Inc. |
Modulators of toll-like receptors
|
US8288404B2
(en)
|
2009-10-06 |
2012-10-16 |
Bristol-Myers Squibb Company |
Pyrrolidine GPR40 modulators
|
AR078522A1
(es)
|
2009-10-15 |
2011-11-16 |
Lilly Co Eli |
Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
|
IN2012DN02984A
(pt)
|
2009-10-22 |
2015-07-31 |
Gilead Sciences Inc |
|
WO2011052756A1
(ja)
|
2009-10-30 |
2011-05-05 |
持田製薬株式会社 |
新規3-ヒドロキシ-5-アリールイソキサゾール誘導体
|
US8871460B2
(en)
|
2009-11-09 |
2014-10-28 |
Neurogenetic Pharmaceuticals, Inc. |
Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
|
CA2782024A1
(en)
|
2009-11-25 |
2011-06-03 |
Schering Corporation |
Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
|
AR078948A1
(es)
|
2009-11-30 |
2011-12-14 |
Lilly Co Eli |
Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
|
PL2513053T3
(pl)
|
2009-12-18 |
2018-03-30 |
Ogeda Sa |
Pochodne kwasu pirolidyno-karboksylowego jako agoniści receptora 43 sprzężonego z białkiem G (GPR43), kompozycja farmaceutyczna i sposoby do zastosowania w leczeniu zaburzeń metabolicznych
|
WO2011076732A1
(en)
|
2009-12-21 |
2011-06-30 |
Euroscreen S.A. |
Compounds, pharmaceutical composition and methods for use in treating gastrointestinal disorders
|
WO2011076734A1
(en)
|
2009-12-21 |
2011-06-30 |
Euroscreen S.A. |
Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
|
JP5002077B2
(ja)
|
2009-12-25 |
2012-08-15 |
持田製薬株式会社 |
新規3−ヒドロキシ−5−アリールイソチアゾール誘導体
|
WO2011080755A1
(en)
|
2009-12-29 |
2011-07-07 |
Advinus Therapeutics Private Limited |
Fused nitrogen heterocyclic compounds, process of preparation and uses thereof
|
WO2011082400A2
(en)
*
|
2010-01-04 |
2011-07-07 |
President And Fellows Of Harvard College |
Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
|
WO2011092284A1
(en)
|
2010-01-29 |
2011-08-04 |
Euroscreen S.A. |
Novel amino acid derivatives and their use as gpr43 receptor modulators
|
CN105622757A
(zh)
|
2010-02-04 |
2016-06-01 |
吉联亚生物科技有限公司 |
结合赖氨酰氧化酶样2(loxl2)的抗体和其使用方法
|
US9186337B2
(en)
|
2010-02-24 |
2015-11-17 |
Oryzon Genomics S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae
|
TW201200522A
(en)
|
2010-03-24 |
2012-01-01 |
Vertex Pharma |
Analogues for the treatment or prevention of flavivirus infections
|
WO2011119858A1
(en)
|
2010-03-24 |
2011-09-29 |
Vertex Pharmaceuticals Incorporated |
Analogues for the treatment or prevention of flavivirus infections
|
RU2012145950A
(ru)
|
2010-03-30 |
2014-05-10 |
Новартис Аг |
Применения ингибиторов dgati
|
US8686048B2
(en)
|
2010-05-06 |
2014-04-01 |
Rhizen Pharmaceuticals Sa |
Immunomodulator and anti-inflammatory compounds
|
KR20130079429A
(ko)
|
2010-05-12 |
2013-07-10 |
벤더르빌트 유니버시티 |
헤테로시클릭 설폰 mglur4 알로스테릭 강화제, 조성물 및 신경 기능이상을 치료하는 방법
|
CA2797089A1
(en)
|
2010-05-13 |
2011-11-17 |
Indiana University Research And Technology Corporation |
Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
|
WO2011146862A1
(en)
|
2010-05-21 |
2011-11-24 |
Bellicum Pharmaceuticals, Inc. |
Methods for inducing selective apoptosis
|
PT2578585T
(pt)
|
2010-05-31 |
2016-09-23 |
Ono Pharmaceutical Co |
Derivado de purinona como inibidor da quinase btk
|
WO2011151436A2
(en)
|
2010-06-04 |
2011-12-08 |
Euroscreen S.A. |
Novel compounds, method for use them and pharmaceutical composition containing them
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
JP2012036168A
(ja)
|
2010-07-15 |
2012-02-23 |
Daiichi Sankyo Co Ltd |
ヘテロ原子を有する環状化合物を含有する医薬組成物
|
US8932980B2
(en)
|
2010-07-20 |
2015-01-13 |
Council Of Scientific & Industrial Research |
Ordered mesoporous titanosilicate and the process for the preparation thereof
|
EP2595613B1
(en)
|
2010-07-22 |
2019-01-09 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Compounds for use in a method of preventing or treating viral infection
|
MA34527B1
(fr)
|
2010-08-27 |
2013-09-02 |
Gilead Biologics Inc |
Anticorps contre la metalloproteinase de matrice 9
|
WO2012036168A1
(ja)
|
2010-09-14 |
2012-03-22 |
北海道公立大学法人札幌医科大学 |
筋ジストロフィーを処置するための組成物
|
US8999967B2
(en)
|
2010-09-29 |
2015-04-07 |
Presidio Pharmaceuticals, Inc. |
Tricyclic fused ring inhibitors of hepatitis C
|
MX340290B
(es)
|
2010-10-01 |
2016-07-04 |
Ventirx Pharmaceuticals Inc |
Uso terapéutico de un agonista de receptor tipo toll y terapia de combinación.
|
WO2012045089A2
(en)
|
2010-10-01 |
2012-04-05 |
Ventirx Pharmaceuticals, Inc. |
Methods for the treatment of allergic diseases
|
CA2813639A1
(en)
|
2010-10-08 |
2012-04-12 |
Mochida Pharmaceutical Co. Ltd. |
Cyclic amide derivative
|
US9474275B2
(en)
|
2010-11-15 |
2016-10-25 |
Bayer Intellectual Property Gmbh |
Cyanoenamines and their use as fungicides
|
WO2012068234A2
(en)
|
2010-11-17 |
2012-05-24 |
Gilead Sciences, Inc. |
Antiviral compounds
|
US20130310379A1
(en)
|
2010-11-19 |
2013-11-21 |
Constellation Pharmaceuticals |
Modulators of methyl modifying enzymes, compositions and uses thereof
|
DK2646425T3
(en)
|
2010-12-01 |
2015-08-24 |
Boehringer Ingelheim Int |
Indanyloxydihydrobenzofuranylacetic acids useful for the treatment of metabolic syndrome.
|
WO2012078802A1
(en)
|
2010-12-08 |
2012-06-14 |
Takeda Pharmaceutical Company Limited |
PREPARATION OF SUBSTITUTED-4,5-DIHYDROPYRROLO[4,3,2-de][2,6]NAPHTHYRIDIN-3(1H)-ONES
|
SG10201510092QA
(en)
|
2010-12-09 |
2016-01-28 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
AR084217A1
(es)
|
2010-12-10 |
2013-05-02 |
Gilead Sciences Inc |
Inhibidores macrociclicos de virus flaviviridae
|
EP2651923A4
(en)
|
2010-12-15 |
2014-06-18 |
Abbvie Inc |
ANTI-VIRAL COMPOUNDS
|
EP2651927A4
(en)
|
2010-12-15 |
2014-06-04 |
Abbvie Inc |
ANTIVIRAL CONNECTIONS
|
WO2012083061A2
(en)
|
2010-12-15 |
2012-06-21 |
Abbott Laboratories |
Anti-viral compounds
|
WO2012083053A2
(en)
|
2010-12-15 |
2012-06-21 |
Abbott Laboratories |
Anti-viral compounds
|
WO2012083048A2
(en)
|
2010-12-15 |
2012-06-21 |
Abbott Laboratories |
Anti-viral compounds
|
EP2655334B1
(en)
|
2010-12-22 |
2018-10-03 |
Eutropics Pharmaceuticals, Inc. |
Compositions and methods useful for treating diseases
|
JP5985509B2
(ja)
|
2011-01-12 |
2016-09-06 |
ベンティアールエックス ファーマシューティカルズ, インコーポレイテッドVentiRx Pharmaceuticals,Inc. |
Toll様受容体調節薬としての置換ベンゾアゼピン
|
CA2824786A1
(en)
|
2011-01-12 |
2012-07-19 |
Ventirx Pharmaceuticals, Inc. |
Substituted benzoazepines as toll-like receptor modulators
|
MX2013008257A
(es)
|
2011-01-19 |
2013-08-12 |
Galapagos Nv |
Derivados de azetidina utiles para el tratamiento de enfermedades metabolicas e inflamatorias.
|
EP3459945A1
(en)
|
2011-01-25 |
2019-03-27 |
The Regents of The University of Michigan |
Bcl-2/bcl-xl inhibitors for use in the treatment of cancer
|
ES2732311T3
(es)
|
2011-02-07 |
2019-11-21 |
Univ Washington |
Compuestos de manósidos y procedimientos de uso de los mismos
|
ES2643389T3
(es)
|
2011-02-12 |
2017-11-22 |
Globeimmune, Inc. |
Producto terapéutico basado en levadura para infección por hepatitis B crónica
|
SG192645A1
(en)
|
2011-02-17 |
2013-09-30 |
Takeda Pharmaceutical |
Production method of optically active dihydrobenzofuran derivative
|
US9464065B2
(en)
|
2011-03-24 |
2016-10-11 |
The Scripps Research Institute |
Compounds and methods for inducing chondrogenesis
|
KR102058946B1
(ko)
|
2011-04-08 |
2019-12-24 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
바이러스 감염 치료를 위한 피리미딘 유도체
|
WO2012136221A1
(en)
|
2011-04-08 |
2012-10-11 |
Syddansk Universitet |
Ortho-fluoro substituted compounds for the treatment of metabolic diseases
|
US8557766B2
(en)
|
2011-04-27 |
2013-10-15 |
Mochida Pharmaceutical Co., Ltd. |
3-hydroxyisothiazole 1-oxide derivatives
|
WO2012154608A1
(en)
|
2011-05-06 |
2012-11-15 |
Intellikine, Llc |
Reactive mtor and pi3 kinase inhibitors and uses thereof
|
JP5659189B2
(ja)
|
2011-05-13 |
2015-01-28 |
富士フイルム株式会社 |
非共鳴2光子吸収材料、非共鳴2光子吸収記録材料、記録媒体、記録再生方法及び非共鳴2光子吸収化合物
|
BR112013029537B1
(pt)
|
2011-05-18 |
2020-06-30 |
Janssen Sciences Ireland Uc |
derivados de quinazolina, seu uso no tratamento de infecções virais e outras doenças e composição farmacêutica que os compreende
|
TWI567061B
(zh)
|
2011-07-01 |
2017-01-21 |
吉李德科學股份有限公司 |
用於治療成癮之化合物
|
WO2013009259A1
(en)
|
2011-07-14 |
2013-01-17 |
Biochromix Pharma Ab |
Novel compounds and their use in therapy
|
TWI537262B
(zh)
|
2011-08-17 |
2016-06-11 |
美國禮來大藥廠 |
供治療糖尿病使用之新穎1,2,3,4-四氫喹啉衍生物
|
WO2013027802A1
(ja)
|
2011-08-23 |
2013-02-28 |
中外製薬株式会社 |
抗腫瘍活性を有する新規な抗ddr1抗体
|
GB201115529D0
(en)
|
2011-09-08 |
2011-10-26 |
Imp Innovations Ltd |
Antibodies, uses and methods
|
US20140235643A1
(en)
|
2011-10-04 |
2014-08-21 |
Gilead Calistoga Llc |
Novel quinoxaline inhibitors of pi3k
|
WO2013057743A1
(en)
|
2011-10-21 |
2013-04-25 |
Connexios Life Sciences Pvt. Ltd |
Process for the preparation of an aryl oxime and salts thereof
|
RS55542B1
(sr)
|
2011-11-29 |
2017-05-31 |
Ono Pharmaceutical Co |
Purinonski derivati hlorovodonika
|
ES2649410T3
(es)
|
2011-12-21 |
2018-01-11 |
Novira Therapeutics Inc. |
Agentes antivirales para la hepatitis B
|
WO2013102626A1
(en)
|
2012-01-04 |
2013-07-11 |
Sanofi |
3-[4-(phenylaminooxalylamino)phenyl]hex-4-ynoic acids, process for preparation thereof and use thereof as a medicament
|
JP6122871B2
(ja)
|
2012-01-12 |
2017-04-26 |
ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. |
多環式化合物誘導体、それらの製造方法および医薬用途
|
US9326973B2
(en)
|
2012-01-13 |
2016-05-03 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
JP6215230B2
(ja)
|
2012-01-16 |
2017-10-18 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
イオンチャネルのモジュレーターとしてのピラン−スピロ環式ピペリジンアミド
|
UY34573A
(es)
|
2012-01-27 |
2013-06-28 |
Gilead Sciences Inc |
Inhibidor de la quinasa que regula la señal de la apoptosis
|
WO2013116562A1
(en)
|
2012-02-03 |
2013-08-08 |
Gilead Calistoga Llc |
Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
|
BR112014019699B1
(pt)
|
2012-02-08 |
2021-12-07 |
Janssen Sciences Ireland Uc |
Derivados de piperidino-pirimidina, seu uso no tratamento de infecções virais e composição farmacêutica que os compreende
|
WO2013122029A1
(ja)
|
2012-02-13 |
2013-08-22 |
武田薬品工業株式会社 |
芳香環化合物
|
JP6095580B2
(ja)
|
2012-02-13 |
2017-03-15 |
武田薬品工業株式会社 |
芳香環化合物
|
IN2014MN01839A
(pt)
|
2012-02-28 |
2015-07-03 |
Piramal Entpr Ltd |
|
US8642585B2
(en)
|
2012-03-26 |
2014-02-04 |
Boehringer Ingelheim International Gmbh |
Indanyloxydihydrobenzofuranylacetic acids
|
ES2575398T3
(es)
|
2012-03-31 |
2016-06-28 |
F. Hoffmann-La Roche Ag |
4-Metil-dihidropirimidinas novedosas para el tratamiento y la profilaxis de la infección por el virus de la hepatitis B
|
US20130267517A1
(en)
|
2012-03-31 |
2013-10-10 |
Hoffmann-La Roche Inc. |
Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
WO2013154163A1
(ja)
|
2012-04-11 |
2013-10-17 |
持田製薬株式会社 |
新規5-アリール-1,2-チアジナン誘導体
|
US8809376B2
(en)
|
2012-04-30 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
Indanyloxydihydrobenzofuranylacetic acids
|
MX2014013752A
(es)
|
2012-05-11 |
2014-12-08 |
Abbvie Inc |
Inhibidores de nampt.
|
WO2013170115A1
(en)
|
2012-05-11 |
2013-11-14 |
Abbvie Inc. |
Pyridazine and pyridine derivatives as nampt inhibitors
|
US8633182B2
(en)
|
2012-05-30 |
2014-01-21 |
Boehringer Ingelheim International Gmbh |
Indanyloxyphenylcyclopropanecarboxylic acids
|
AR091279A1
(es)
|
2012-06-08 |
2015-01-21 |
Gilead Sciences Inc |
Inhibidores macrociclicos de virus flaviviridae
|
AU2013270672B2
(en)
|
2012-06-08 |
2017-10-19 |
Gilead Sciences, Inc. |
Macrocyclic inhibitors of flaviviridae viruses
|
KR20150040266A
(ko)
|
2012-06-08 |
2015-04-14 |
길리애드 사이언시즈, 인코포레이티드 |
플라비바이러스과 바이러스의 마크로시클릭 저해인자
|
WO2014014530A1
(en)
|
2012-07-17 |
2014-01-23 |
Mylari Banavara L |
Ursolic acid salts for treating diabetes and obesity
|
JP2015127299A
(ja)
|
2012-07-19 |
2015-07-09 |
武田薬品工業株式会社 |
固形製剤
|
WO2014019186A1
(en)
|
2012-08-02 |
2014-02-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
EA029266B1
(ru)
|
2012-08-10 |
2018-02-28 |
Янссен Сайенсиз Айрлэнд Юси |
Алкилпиримидиновые производные для лечения вирусных инфекций
|
ES2711425T3
(es)
|
2012-08-27 |
2019-05-03 |
Allergan Inc |
Espesamiento de la córnea central reducido mediante el uso de profármacos de éster hidrófilos de beta-clorociclopentanos
|
BR112015004161B8
(pt)
|
2012-08-28 |
2022-11-08 |
Janssen Sciences Ireland Uc |
Derivado bicíclico fusionado de sulfamoíla e seu uso no tratamento e prevenção de infecção por vírus da hepatite b, bem como composição farmacêutica e produto que o compreende
|
TW201920090A
(zh)
|
2012-08-28 |
2019-06-01 |
愛爾蘭商健生科學愛爾蘭無限公司 |
胺磺醯基-芳醯胺類及其做為治療b型肝炎之醫藥劑的用途
|
EP2892893B2
(en)
|
2012-09-10 |
2019-10-16 |
F.Hoffmann-La Roche Ag |
6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
US20140073631A1
(en)
|
2012-09-12 |
2014-03-13 |
Vymed Corporation |
Antiviral and antimicrobial compounds
|
AR092662A1
(es)
|
2012-09-24 |
2015-04-29 |
Gilead Sciences Inc |
Anticuerpos anti-ddr1
|
HUE033380T2
(en)
|
2012-10-02 |
2017-11-28 |
Gilead Sciences Inc |
Inhibitors of histone demethylases
|
DK2906563T3
(en)
|
2012-10-10 |
2018-06-06 |
Janssen Sciences Ireland Uc |
PYRROLO [3,2-D] PYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS AND OTHER DISEASES
|
US10034939B2
(en)
*
|
2012-10-26 |
2018-07-31 |
The University Of Chicago |
Synergistic combination of immunologic inhibitors for the treatment of cancer
|
US20140128333A1
(en)
|
2012-11-02 |
2014-05-08 |
Maqui New Life S.A. |
Compounds, Compositions, and Methods for Decreasing Intestinal Glucose Uptake and Inducing Incretin Release
|
TWI692469B
(zh)
|
2012-11-09 |
2020-05-01 |
南韓商Lg化學股份有限公司 |
Gpr40受體促效劑,製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物
|
KR101268466B1
(ko)
|
2012-11-12 |
2013-06-04 |
유병수 |
사축형 윈드 터빈
|
PL2925729T3
(pl)
|
2012-11-16 |
2018-04-30 |
Janssen Sciences Ireland Uc |
Heterocykliczne podstawione pochodne 2-amino-chinazoliny do leczenia infekcji wirusowych
|
CN105121426B
(zh)
|
2012-11-16 |
2017-03-29 |
百时美施贵宝公司 |
吡咯烷gpr40调节剂
|
TW201427971A
(zh)
|
2012-11-16 |
2014-07-16 |
必治妥美雅史谷比公司 |
二氫吡唑gpr40調節劑
|
CA2891535A1
(en)
|
2012-11-16 |
2014-05-22 |
Bristol-Myers Squibb Company |
Dihydropyrazole gpr40 modulators
|
AU2013348167A1
(en)
|
2012-11-20 |
2015-05-28 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
|
WO2014082918A1
(en)
|
2012-11-28 |
2014-06-05 |
Boehringer Ingelheim International Gmbh |
New indanyloxydihydrobenzofuranylacetic acids
|
US8987461B2
(en)
|
2012-12-06 |
2015-03-24 |
Quanticel Pharmaceuticals, Inc. |
Histone demethylase inhibitors
|
EP2928886B1
(en)
|
2012-12-07 |
2016-11-02 |
Boehringer Ingelheim International GmbH |
New indanyloxydihydrobenzofuranylacetic acids
|
PL2934145T3
(pl)
|
2012-12-19 |
2018-04-30 |
Celgene Quanticel Research, Inc. |
Inhibitory demetylazy histonowej
|
WO2014100767A1
(en)
|
2012-12-21 |
2014-06-26 |
Gilead Calistoga Llc |
Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors
|
JP6273621B2
(ja)
|
2012-12-21 |
2018-02-07 |
セルジーン クオンティセル リサーチ,インク. |
ヒストンデメチラーゼ阻害剤
|
EP2941426B1
(en)
|
2012-12-21 |
2018-06-13 |
Gilead Calistoga LLC |
Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
|
JP6314335B2
(ja)
|
2013-02-06 |
2018-04-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新しいインダニルオキシジヒドロベンゾフラニル酢酸
|
BR112015020118B1
(pt)
|
2013-02-21 |
2022-02-22 |
Janssen Sciences Ireland Uc |
Derivados de 2-aminopirimidina para o tratamento de infecções virais, composição farmacêutica e uso
|
RU2015140066A
(ru)
|
2013-02-22 |
2017-03-30 |
Мерк Шарп И Доум Корп. |
Противодиабетические бициклические соединения
|
US9642843B2
(en)
|
2013-02-27 |
2017-05-09 |
The Regents Of The University Of Michigan |
Pharmaceutical compounds and use of same in cancer and tauopathies
|
PE20151667A1
(es)
|
2013-02-27 |
2015-11-27 |
Epitherapeutics Aps |
Inhibidores de histona desmetilasas
|
CA2899706C
(en)
|
2013-02-28 |
2021-10-19 |
Janssen Sciences Ireland Uc |
Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
|
CN105209448B
(zh)
|
2013-02-28 |
2018-09-14 |
株式会社蒂奥姆生物 |
三环化合物及其用途
|
US8993771B2
(en)
|
2013-03-12 |
2015-03-31 |
Novira Therapeutics, Inc. |
Hepatitis B antiviral agents
|
EP2968282B1
(en)
|
2013-03-12 |
2018-05-09 |
Celgene Quanticel Research, Inc. |
Histone dementhylase inhibitors
|
KR20150130491A
(ko)
|
2013-03-13 |
2015-11-23 |
제넨테크, 인크. |
피라졸로 화합물 및 그것의 용도
|
CA2903081A1
(en)
|
2013-03-14 |
2014-09-25 |
Quanticel Pharmaceuticals, Inc. |
Histone demethylase inhibitors
|
ES2644828T3
(es)
|
2013-03-15 |
2017-11-30 |
Quanticel Pharmaceuticals Inc |
Inhibidores de histona desmetilasa
|
US9763905B2
(en)
|
2013-03-15 |
2017-09-19 |
The Children's Medical Center Corporation |
Therapeutic target for the treatment of cancers and related therapies and methods
|
CN104059039B
(zh)
|
2013-03-22 |
2017-03-15 |
正大天晴药业集团股份有限公司 |
具有gpr40受体功能调节作用的稠环化合物
|
WO2014161888A1
(en)
|
2013-04-03 |
2014-10-09 |
Janssen R&D Ireland |
N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
|
CN104109115B
(zh)
|
2013-04-16 |
2016-11-23 |
中国科学院上海药物研究所 |
一种含氮杂环链接的苯丙酸类化合物、其药物组合物、制备方法和用途
|
WO2014170842A2
(en)
|
2013-04-17 |
2014-10-23 |
Piramal Enterprises Limited |
Substituted alkyl carboxylic acid derivatives as gpr agonists
|
KR101569522B1
(ko)
|
2013-04-18 |
2015-11-17 |
현대약품 주식회사 |
신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
|
TWI527811B
(zh)
|
2013-05-09 |
2016-04-01 |
吉李德科學股份有限公司 |
作爲溴結構域抑制劑的苯並咪唑衍生物
|
EA201592126A1
(ru)
|
2013-05-17 |
2016-05-31 |
Ф. Хоффманн-Ля Рош Аг |
6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
|
RS57999B1
(sr)
|
2013-05-17 |
2019-01-31 |
Janssen Sciences Ireland Uc |
Derivati sulfamoiltiofenamida i njihova primena kao lekovi za tretman hepatitisa b
|
JO3603B1
(ar)
|
2013-05-17 |
2020-07-05 |
Janssen Sciences Ireland Uc |
مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
|
WO2014187343A1
(zh)
|
2013-05-22 |
2014-11-27 |
四川海思科制药有限公司 |
苯并呋喃衍生物、其制备方法及其在医药上的应用
|
TWI644909B
(zh)
|
2013-06-14 |
2018-12-21 |
基利科學股份有限公司 |
磷脂酸肌醇3-激酶抑制劑
|
CN104507921B
(zh)
|
2013-07-02 |
2017-02-22 |
四川海思科制药有限公司 |
苯并环丁烯类衍生物、其制备方法及其在医药上的应用
|
WO2015003146A1
(en)
|
2013-07-03 |
2015-01-08 |
Georgetown University |
Boronic acid derivatives of resveratrol for activating deacetylase enzymes
|
US20160145304A1
(en)
|
2013-07-12 |
2016-05-26 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
Cystobactamides
|
CN104341407A
(zh)
|
2013-07-24 |
2015-02-11 |
黄传满 |
喹唑啉类化合物及其制备方法和用途
|
AU2014294997B2
(en)
|
2013-07-25 |
2018-03-22 |
Janssen Sciences Ireland Uc |
Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
|
WO2015010655A1
(zh)
|
2013-07-26 |
2015-01-29 |
四川海思科制药有限公司 |
三元并环羧酸类衍生物、其制备方法及其在医药上的应用
|
MY176803A
(en)
|
2013-07-30 |
2020-08-21 |
Gilead Connecticut Inc |
Polymorph of syk inhibitors
|
HUE039259T2
(hu)
|
2013-08-09 |
2018-12-28 |
Takeda Pharmaceuticals Co |
Aromás vegyület
|
CN104418801B
(zh)
|
2013-08-19 |
2016-10-05 |
上海润诺生物科技有限公司 |
苯并哌啶环与苯并吗啉环类化合物、其制法及医药应用
|
EP3036237A4
(en)
|
2013-08-23 |
2017-01-25 |
Fujian Haixi Pharmaceuticals Co. Ltd |
Carboxylic acid compounds in treatment of diabetes mellitus
|
WO2015031036A1
(en)
|
2013-08-26 |
2015-03-05 |
Purdue Pharma L.P. |
Azaspiro[4.5] decane derivatives and use thereof
|
WO2015028960A1
(en)
|
2013-08-28 |
2015-03-05 |
Piramal Enterprises Limited |
Substituted heterocyclic derivatives as gpr agonists and uses thereof
|
WO2015032328A1
(zh)
|
2013-09-03 |
2015-03-12 |
四川海思科制药有限公司 |
茚满衍生物及其制备方法和在医药上的应用
|
CN105705489B
(zh)
*
|
2013-09-04 |
2019-04-26 |
百时美施贵宝公司 |
用作免疫调节剂的化合物
|
AU2014316682B2
(en)
|
2013-09-06 |
2018-11-22 |
Aurigene Discovery Technologies Limited |
1,2,4-oxadiazole derivatives as immunomodulators
|
HUE052856T2
(hu)
|
2013-09-11 |
2021-05-28 |
Inst Nat Sante Rech Med |
Eljárások és gyógyászati készítmények Hepatitis B vírus fertõzés kezelésére
|
EP3049396B1
(en)
|
2013-09-26 |
2017-11-15 |
Boehringer Ingelheim International GmbH |
Process and intermediates for preparing indanyloxydihydrobenzofuranyl acetic acid derivatives as gpr40 agonists
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
KR102290189B1
(ko)
|
2013-10-23 |
2021-08-17 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
카르복스아미드 유도체 및 b형 간염 치료용 의약으로서의 이의 용도
|
CN104592211B
(zh)
|
2013-10-31 |
2018-10-16 |
广东东阳光药业有限公司 |
联苯类化合物及其用途
|
IN2013MU03577A
(pt)
|
2013-11-14 |
2015-07-31 |
Cadila Healthcare Ltd |
|
KR20160127714A
(ko)
|
2013-11-14 |
2016-11-04 |
노비라 테라퓨틱스, 인코포레이티드 |
아제판 유도체 및 b형 간염 감염의 치료 방법
|
EP3068768B1
(en)
|
2013-11-15 |
2019-07-31 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
WO2015076800A1
(en)
|
2013-11-21 |
2015-05-28 |
Ptc Therapeutics, Inc. |
Substituted pyridine and pyrazine bmi-1 inhibitors
|
DK3074008T3
(da)
|
2013-11-27 |
2019-10-21 |
Epics Therapeutics |
Forbindelser, farmaceutisk sammensætning og fremgangsmåder til anvendelse i behandling af inflammation
|
JP6441928B2
(ja)
|
2013-11-28 |
2018-12-19 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規インダニルオキシフェニルシクロプロパンカルボン酸
|
EP3076959B1
(en)
|
2013-12-04 |
2018-07-04 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
WO2015085238A1
(en)
|
2013-12-05 |
2015-06-11 |
The Regents Of The University Of California, A California Corporation |
Inhibitors of lpxc
|
TW201609722A
(zh)
|
2013-12-13 |
2016-03-16 |
美國禮來大藥廠 |
新穎三唑并吡啶化合物
|
WO2015089809A1
(en)
|
2013-12-19 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Antidiabetic substituted heteroaryl compounds
|
TWI662037B
(zh)
|
2013-12-23 |
2019-06-11 |
美商基利科學股份有限公司 |
脾酪胺酸激酶抑制劑
|
US9290505B2
(en)
|
2013-12-23 |
2016-03-22 |
Gilead Sciences, Inc. |
Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
|
KR20160095117A
(ko)
|
2014-01-10 |
2016-08-10 |
일라이 릴리 앤드 캄파니 |
페닐-트리아졸로-피리딘 화합물
|
JP6170255B2
(ja)
|
2014-01-10 |
2017-07-26 |
イーライ リリー アンド カンパニー |
イソプロピルトリアゾロピリジン化合物
|
US9169212B2
(en)
|
2014-01-16 |
2015-10-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
US9181288B2
(en)
|
2014-01-16 |
2015-11-10 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
AU2015212903A1
(en)
|
2014-01-30 |
2016-05-19 |
F. Hoffmann-La Roche Ag |
Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection
|
WO2015119899A1
(en)
|
2014-02-06 |
2015-08-13 |
Merck Sharp & Dohme Corp. |
Antidiabetic compounds
|
KR20160110419A
(ko)
|
2014-02-06 |
2016-09-21 |
얀센 사이언시즈 아일랜드 유씨 |
술파모일피롤아미드 유도체 및 b형 간염 치료용 의약으로서의 이의 용도
|
LT3114128T
(lt)
|
2014-03-07 |
2019-03-25 |
F. Hoffmann-La Roche Ag |
Nauji 6 padėtyje kondensuoti heteroarildihidropirimidinai, skirti hepatito b virusinės infekcijos gydymui ir profilaktikai
|
WO2015140717A1
(en)
|
2014-03-18 |
2015-09-24 |
Iteos Therapeutics |
Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use
|
US9400280B2
(en)
|
2014-03-27 |
2016-07-26 |
Novira Therapeutics, Inc. |
Piperidine derivatives and methods of treating hepatitis B infections
|
MA52856B1
(fr)
|
2014-04-04 |
2022-03-31 |
Pfizer |
Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4
|
UA121386C2
(uk)
|
2014-04-04 |
2020-05-25 |
Айомет Фарма Лтд |
Похідні індолу, фармацевтична композиція, яка їх містить, та способи їх застосування
|
SG10201808825XA
(en)
|
2014-04-10 |
2018-11-29 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Defined composition gene modified t-cell products
|
US9850225B2
(en)
|
2014-04-14 |
2017-12-26 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
CN106458987B
(zh)
|
2014-05-07 |
2019-09-24 |
百时美施贵宝公司 |
用于治疗疾病诸如糖尿病的吡咯烷gpr40调节剂
|
WO2015171757A1
(en)
|
2014-05-07 |
2015-11-12 |
Bristol-Myers Squibb Company |
Pyrrolidine gpr40 modulators
|
TN2016000444A1
(en)
|
2014-05-07 |
2018-04-04 |
Bristol Myers Squibb Co |
Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes.
|
RU2016146365A
(ru)
|
2014-05-13 |
2018-06-19 |
Ф. Хоффманн-Ля Рош Аг |
Новые дигидрохинолизиноны для лечения и профилактики заражения вирусом гепатита b
|
WO2015176267A1
(en)
|
2014-05-22 |
2015-11-26 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
CN106535884A
(zh)
|
2014-06-06 |
2017-03-22 |
弗雷克萨斯生物科学公司 |
免疫调节剂
|
CN106573007A
(zh)
|
2014-06-13 |
2017-04-19 |
罗切斯特大学 |
小分子外排泵抑制剂
|
GB201411239D0
(en)
|
2014-06-25 |
2014-08-06 |
Takeda Pharmaceutical |
Novel compounds
|
GB201411236D0
(en)
|
2014-06-25 |
2014-08-06 |
Takeda Pharmaceutical |
Novel compounds
|
TW201613878A
(en)
|
2014-07-09 |
2016-04-16 |
Janssen Pharmaceutica Nv |
Pyrazine GPR40 agonists for the treatment of type II diabetes
|
WO2016012470A1
(en)
|
2014-07-25 |
2016-01-28 |
F. Hoffmann-La Roche Ag |
New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid
|
WO2016018729A1
(en)
|
2014-07-29 |
2016-02-04 |
Merck Sharp & Dohme Corp. |
Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein
|
WO2016019587A1
(en)
|
2014-08-08 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
[7, 6]-fused bicyclic antidiabetic compounds
|
WO2016022742A1
(en)
|
2014-08-08 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
US10662171B2
(en)
|
2014-08-08 |
2020-05-26 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
EP3177285B1
(en)
|
2014-08-08 |
2020-09-23 |
Merck Sharp & Dohme Corp. |
[5,6]-fused bicyclic antidiabetic compounds
|
BR112017002970B1
(pt)
|
2014-08-14 |
2023-04-11 |
F. Hoffmann-La Roche Ag |
Novas piridazonas e triazinonas para o tratamento e profilaxia da infecção pelo vírus da hepatite b
|
GB201414730D0
(en)
|
2014-08-19 |
2014-10-01 |
Tpp Global Dev Ltd |
Pharmaceutical compound
|
WO2016032120A1
(ko)
|
2014-08-27 |
2016-03-03 |
씨제이헬스케어 주식회사 |
신규한 아미노-페닐-설포닐-아세테이트 유도체 및 이의 용도
|
KR20170040805A
(ko)
|
2014-08-27 |
2017-04-13 |
길리애드 사이언시즈, 인코포레이티드 |
히스톤 데메틸라제를 억제하기 위한 화합물 및 방법
|
TWI805109B
(zh)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
EA034496B1
(ru)
|
2014-09-11 |
2020-02-13 |
Бристол-Майерс Сквибб Компани |
Макроциклические ингибиторы белок/белковых взаимодействий pd-1/pd-l1 и cd80(b7-1)/pd-l1
|
UY35733A
(es)
|
2014-09-12 |
2016-04-01 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Inhibidores macrocíclicos de las interacciones proteína/proteína pd-1/pd-l1 y cd80(b7-1)/pd-l1 i.p.c.
|
AU2015317566B2
(en)
|
2014-09-19 |
2019-10-10 |
Mackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital |
Benzo-heterocyclic compounds and their applications
|
CN106715419A
(zh)
|
2014-09-26 |
2017-05-24 |
吉利德科学公司 |
用作tank‑结合激酶抑制剂化合物的氨基三嗪衍生物
|
CN107912040B
(zh)
|
2014-10-10 |
2021-04-06 |
基因泰克公司 |
作为组蛋白脱甲基酶抑制剂的吡咯烷酰胺化合物
|
EP3206691B1
(en)
|
2014-10-14 |
2018-09-19 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
WO2016060517A2
(ko)
|
2014-10-17 |
2016-04-21 |
현대약품 주식회사 |
신규한 3-(4- (벤질옥시)페닐)핵스- 4-이노익 산 유도체 및 다른 유효 성분을 포함하는 대사성 질환의 예방 또는 치료용 복합제제
|
EA034931B1
(ru)
|
2014-10-24 |
2020-04-08 |
Бристол-Майерс Сквибб Компани |
Индолкарбоксамидные соединения
|
KR101857146B1
(ko)
|
2014-10-28 |
2018-05-11 |
삼성에스디아이 주식회사 |
유기 광전자 소자 및 표시 장치
|
CN107108556B
(zh)
|
2014-11-03 |
2020-09-29 |
艾欧米制药有限公司 |
药用化合物
|
US9637485B2
(en)
|
2014-11-03 |
2017-05-02 |
Hoffmann-La Roche Inc. |
6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
|
GB201419579D0
(en)
|
2014-11-03 |
2014-12-17 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
AR102537A1
(es)
|
2014-11-05 |
2017-03-08 |
Flexus Biosciences Inc |
Agentes inmunomoduladores
|
UY36390A
(es)
|
2014-11-05 |
2016-06-01 |
Flexus Biosciences Inc |
Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
|
US9856292B2
(en)
|
2014-11-14 |
2018-01-02 |
Bristol-Myers Squibb Company |
Immunomodulators
|
US11266739B2
(en)
|
2014-12-03 |
2022-03-08 |
Juno Therapeutics, Inc. |
Methods and compositions for adoptive cell therapy
|
EP3227337A1
(en)
|
2014-12-05 |
2017-10-11 |
F. Hoffmann-La Roche AG |
Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists
|
WO2016100236A2
(en)
|
2014-12-15 |
2016-06-23 |
Bellicum Pharmaceuticals, Inc. |
Methods for controlled elimination of therapeutic cells
|
US9676793B2
(en)
|
2014-12-23 |
2017-06-13 |
Hoffmann-Laroche Inc. |
Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
|
AR103222A1
(es)
|
2014-12-23 |
2017-04-26 |
Hoffmann La Roche |
Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina
|
WO2016107832A1
(en)
|
2014-12-30 |
2016-07-07 |
F. Hoffmann-La Roche Ag |
Novel tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis b virus infection
|
JP2018504891A
(ja)
|
2014-12-31 |
2018-02-22 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
リアルタイムPCRによる細胞溶解物からのHBV cccDNA定量化のための新規ハイスループット法
|
BR112017014770A2
(pt)
|
2015-01-08 |
2018-01-16 |
Advinus Therapeutics Ltd |
compostos bicíclicos, composições e aplicações médicas dos mesmos
|
MA41338B1
(fr)
|
2015-01-16 |
2019-07-31 |
Hoffmann La Roche |
Composés de pyrazine pour le traitement de maladies infectieuses
|
JP2018502604A
(ja)
|
2015-01-27 |
2018-02-01 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
組換えHBV cccDNA、その作製方法およびその使用
|
US20160222060A1
(en)
|
2015-02-04 |
2016-08-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
CN108025006A
(zh)
|
2015-02-06 |
2018-05-11 |
尤尼蒂生物技术公司 |
化合物及在治疗衰老相关病症中的用途
|
EP3256471B1
(en)
|
2015-02-11 |
2018-12-12 |
F. Hoffmann-La Roche AG |
Novel 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
|
WO2016128908A1
(en)
|
2015-02-12 |
2016-08-18 |
Advinus Therapeutics Limited |
Bicyclic compounds, compositions and medicinal applications thereof
|
CN107427477B
(zh)
|
2015-03-10 |
2021-11-26 |
奥瑞基尼探索技术有限公司 |
作为免疫调节剂的1,2,4-噁二唑和噻二唑化合物
|
MX2017011611A
(es)
|
2015-03-10 |
2018-03-23 |
Aurigene Discovery Tech Ltd |
Compuestos de tiadiazol y 1,3,4-oxadiazol 3-sustituidos como inmunomoduladores.
|
KR20170123317A
(ko)
|
2015-03-10 |
2017-11-07 |
오리진 디스커버리 테크놀로지스 리미티드 |
면역조절제로서의 3-치환된-1,2,4-옥사다이아졸 및 티아다이아졸 화합물
|
EA201791629A1
(ru)
|
2015-03-10 |
2018-02-28 |
Ауриджен Дискавери Текнолоджис Лимитед |
1,3,4-оксадиазольные и тиадиазольные соединения в качестве иммуномодуляторов
|
CU20170116A7
(es)
|
2015-03-10 |
2018-06-05 |
Aurigene Discovery Tech Ltd |
Compuestos cíclicos terapéuticos como inmunomoduladores
|
CN104876912B
(zh)
|
2015-04-08 |
2017-07-21 |
苏州云轩医药科技有限公司 |
Wnt信号通路抑制剂及其应用
|
CA2985642A1
(en)
|
2015-05-15 |
2016-11-24 |
Gilead Sciences, Inc. |
Benzimidazole and imadazopyridine carboximidamide compounds having activity as inhibitors of indoleamine 2,3-dioxygenase
|
MA43344A
(fr)
|
2015-05-29 |
2018-04-11 |
Juno Therapeutics Inc |
Composition et procédés de régulation des interactions inhibitrices dans les cellules génétiquement modifiées
|
TWI703150B
(zh)
|
2015-06-04 |
2020-09-01 |
美商庫拉腫瘤技術股份有限公司 |
用於抑制menin及mll蛋白之交互作用的方法及組合物
|
WO2016197987A1
(zh)
|
2015-06-12 |
2016-12-15 |
杭州英创医药科技有限公司 |
作为Syk抑制剂和/或Syk-HDAC双重抑制剂的杂环化合物
|
EP3322420B1
(en)
|
2015-07-13 |
2021-12-29 |
Merck Sharp & Dohme Corp. |
Bicyclic heterocycles as inhibitors of cholesterol ester transfer protein
|
WO2017025368A1
(en)
|
2015-08-07 |
2017-02-16 |
Boehringer Ingelheim International Gmbh |
Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
WO2017027310A1
(en)
|
2015-08-12 |
2017-02-16 |
Janssen Pharmaceutica Nv |
Gpr40 agonists for the treatment of type ii diabetes
|
US9920040B2
(en)
|
2015-08-12 |
2018-03-20 |
Janssen Pharmaceutica Nv |
GPR40 agonists for the treatment of type II diabetes
|
US9856245B2
(en)
|
2015-08-12 |
2018-01-02 |
Janssen Pharmaceutica Nv |
GPR40 agonists for the treatment of type II diabetes
|
WO2017031392A1
(en)
|
2015-08-20 |
2017-02-23 |
University Of Florida Research Foundation, Incorporated |
Lipid compounds for treatment of obesity, hypertension and metabolic syndrome
|
JP2018526405A
(ja)
|
2015-09-09 |
2018-09-13 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
[{[2,3−ジヒドロ−1H−インデン−1−イル]アミノ}−2H,3H−フロ[3,2−b]ピリジン−3−イル]酢酸、それらの医薬組成物および使用
|
EP3350320A1
(en)
|
2015-09-17 |
2018-07-25 |
Novartis AG |
Car t cell therapies with enhanced efficacy
|
US10745382B2
(en)
|
2015-10-15 |
2020-08-18 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
MA52119A
(fr)
|
2015-10-19 |
2018-08-29 |
Ncyte Corp |
Composés hétérocycliques utilisés comme immunomodulateurs
|
MA43172A
(fr)
|
2015-11-04 |
2018-09-12 |
Incyte Corp |
Compositions pharmaceutiques et méthodes d'inhibition d'indolamine 2,3-dioxygénase et leurs indications
|
SG11201804152RA
(en)
|
2015-11-19 |
2018-06-28 |
Incyte Corp |
Heterocyclic compounds as immunomodulators
|
KR20180093990A
(ko)
|
2015-12-07 |
2018-08-22 |
고쿠리츠 다이가쿠 호진 교토 다이가쿠 |
Pd-1 시그널 저해제의 병용 요법
|
MA44075A
(fr)
|
2015-12-17 |
2021-05-19 |
Incyte Corp |
Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
|
WO2017112730A1
(en)
|
2015-12-22 |
2017-06-29 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
US10800780B2
(en)
|
2015-12-24 |
2020-10-13 |
Genentech, Inc. |
TDO2 Inhibitors
|
EP3190103A1
(en)
*
|
2016-01-08 |
2017-07-12 |
Rijksuniversiteit Groningen |
Inhibitors of the pd-1/pd-l1 protein/protein interaction
|
CA3014774A1
(en)
|
2016-02-17 |
2017-08-24 |
Children's Medical Center Corporation |
Ffa1 (gpr40) as a therapeutic target for neural angiogenesis diseases or disorders
|
US10143746B2
(en)
|
2016-03-04 |
2018-12-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
US9798514B2
(en)
|
2016-03-09 |
2017-10-24 |
Spotify Ab |
System and method for color beat display in a media content environment
|
WO2017162284A1
(de)
|
2016-03-23 |
2017-09-28 |
Symrise Ag |
Homovanillinsäure-ester zum reduzieren oder inhibieren der fettsäureaufnahme im dünndarm
|
US10676458B2
(en)
|
2016-03-29 |
2020-06-09 |
Merch Sharp & Dohne Corp. Rahway |
Antidiabetic bicyclic compounds
|
US10358463B2
(en)
|
2016-04-05 |
2019-07-23 |
Bristol-Myers Squibb Company |
Immunomodulators
|
US10195178B2
(en)
|
2016-04-11 |
2019-02-05 |
Janssen Pharmaceutica Nv |
GPR40 agonists in anti-diabetic drug combinations
|
US10106553B2
(en)
|
2016-04-11 |
2018-10-23 |
Janssen Pharmaceutica Nv |
Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes
|
WO2017180769A1
(en)
|
2016-04-13 |
2017-10-19 |
Capten Therapeutics Inc. |
Small molecules for immunogenic treatment of cancer
|
ES2906460T3
(es)
|
2016-05-06 |
2022-04-18 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
US10882833B2
(en)
|
2016-05-23 |
2021-01-05 |
Institute Of Materia Medica, Chinese Academy Of Medical Sciences |
Phenylate derivative, preparation method therefor, and pharmaceutical composition and uses thereof
|
WO2017201683A1
(en)
|
2016-05-25 |
2017-11-30 |
Merck Sharp & Dohme Corp. |
Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists
|
ES2905980T3
(es)
|
2016-05-26 |
2022-04-12 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
CN109195989A
(zh)
|
2016-05-26 |
2019-01-11 |
默克专利股份有限公司 |
用于癌症治疗的pd-1/pd-l1抑制剂
|
PL3472167T3
(pl)
|
2016-06-20 |
2022-12-19 |
Incyte Corporation |
Związki heterocykliczne jako immunomodulatory
|
KR102401963B1
(ko)
|
2016-06-27 |
2022-05-25 |
케모센트릭스, 인크. |
면역조절제 화합물
|
KR102491992B1
(ko)
|
2016-07-08 |
2023-01-25 |
브리스톨-마이어스 스큅 컴퍼니 |
면역조정제로서 유용한 1,3-디히드록시-페닐 유도체
|
WO2018026971A1
(en)
|
2016-08-03 |
2018-02-08 |
Arising International, Llc |
Symmetric or semi-symmetric compounds useful as immunomodulators
|
EP3281937A1
(en)
|
2016-08-09 |
2018-02-14 |
Dompé farmaceutici S.p.A. |
Sulfonamides as gpr40- and gpr120-agonists
|
US10563620B2
(en)
|
2016-08-12 |
2020-02-18 |
Rolls-Royce North American Technologies Inc. |
Expandable exhaust cone
|
ES2941716T3
(es)
|
2016-08-29 |
2023-05-25 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
US10144706B2
(en)
|
2016-09-01 |
2018-12-04 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
US10734026B2
(en)
|
2016-09-01 |
2020-08-04 |
Facebook, Inc. |
Systems and methods for dynamically providing video content based on declarative instructions
|
WO2018045142A1
(en)
*
|
2016-09-02 |
2018-03-08 |
Polaris Pharmaceuticals, Inc. |
Immune checkpoint inhibitors, compositions and methods thereof
|
WO2018051254A1
(en)
|
2016-09-14 |
2018-03-22 |
Aurigene Discovery Technologies Limited |
Cyclic substituted-1,2,4-oxadiazole compounds as immunomodulators
|
WO2018051255A1
(en)
|
2016-09-14 |
2018-03-22 |
Aurigene Discovery Technologies Limited |
Cyclic substituted-1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
|
WO2018053302A1
(en)
|
2016-09-19 |
2018-03-22 |
Ensemble Therapeutics Corporation |
Macrocyclic compounds for the inhibition of indoleamine-2,3-dioxygenase activity and use thereof
|
US10988433B2
(en)
|
2016-10-25 |
2021-04-27 |
Janssen Pharmaceutica Nv |
Cyclohexyl GPR40 agonists for the treatment of type II diabetes
|
CN110088089B
(zh)
|
2016-10-25 |
2023-08-29 |
勃林格殷格翰国际有限公司 |
苄基氨基吡啶基环丙烷甲酸、药物组合物及其用途
|
US10125101B2
(en)
|
2016-11-28 |
2018-11-13 |
Boehringer Ingelheim International Gmbh |
Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
US11072602B2
(en)
|
2016-12-06 |
2021-07-27 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
KR102007633B1
(ko)
|
2016-12-15 |
2019-08-06 |
일동제약(주) |
신규 페닐 프로피온 산 유도체 및 이의 용도
|
ES2891528T3
(es)
|
2016-12-20 |
2022-01-28 |
Bristol Myers Squibb Co |
Compuestos útiles como inmunomoduladores
|
RU2019122602A
(ru)
|
2016-12-20 |
2021-01-22 |
Мерк Шарп И Доум Корп. |
Комбинации антагонистов pd-1 и циклических динуклеотидных агонистов sting для лечения рака
|
WO2018118670A1
(en)
|
2016-12-20 |
2018-06-28 |
Merck Sharp & Dohme Corp. |
Antidiabetic spirochroman compounds
|
TW201835049A
(zh)
|
2016-12-22 |
2018-10-01 |
美商英塞特公司 |
作為免疫調節劑之雜環化合物
|
US20180179201A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
US20180177784A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
BR112019012993A2
(pt)
|
2016-12-22 |
2019-12-03 |
Incyte Corp |
derivados de benzo-oxazol como imunomoduladores
|
CR20190317A
(es)
|
2016-12-22 |
2019-09-13 |
Incyte Corp |
Compuestos inmunomodulares y métodos de uso
|
EP3558973B1
(en)
|
2016-12-22 |
2021-09-15 |
Incyte Corporation |
Pyridine derivatives as immunomodulators
|
US10654815B2
(en)
|
2016-12-29 |
2020-05-19 |
Shenzhen Chipscreen Biosciences Co., Ltd. |
Urea compound and preparation method and application thereof
|
CN110177773B
(zh)
|
2017-01-26 |
2023-08-25 |
勃林格殷格翰国际有限公司 |
苄基氨基吡啶基环丙烷羧酸、其药物组合物及其用途
|
CN110248929B
(zh)
|
2017-01-26 |
2023-05-12 |
勃林格殷格翰国际有限公司 |
苄基氨基吡嗪基环丙烷甲酸、其药物组合物和用途
|
WO2018138030A1
(en)
|
2017-01-26 |
2018-08-02 |
Boehringer Ingelheim International Gmbh |
Benzyloxypyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
US10253004B2
(en)
|
2017-01-26 |
2019-04-09 |
Boehringer Ingelheim International Gmbh |
Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
CN110198928B
(zh)
|
2017-01-26 |
2023-08-29 |
勃林格殷格翰国际有限公司 |
苄氧基吡啶基环丙烷甲酸、其药物组合物和用途
|
US10550127B1
(en)
|
2017-02-08 |
2020-02-04 |
Boehringer Ingelheim International Gmbh |
Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes
|
EP3596075B1
(en)
|
2017-03-15 |
2023-10-11 |
F. Hoffmann-La Roche AG |
Azaindoles as inhibitors of hpk1
|
GB201704714D0
(en)
|
2017-03-24 |
2017-05-10 |
Caldan Therapeutics Ltd |
Pharmaceutical compounds
|
US11046675B2
(en)
|
2017-03-27 |
2021-06-29 |
Bristol-Myers Squibb Company |
Substituted isoquionline derivatives as immunomudulators
|
AU2018244935A1
(en)
|
2017-03-30 |
2019-08-15 |
F. Hoffmann-La Roche Ag |
Naphthyridines as inhibitors of HPK1
|
MA48994A
(fr)
|
2017-03-30 |
2020-02-05 |
Hoffmann La Roche |
Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
|
AR111199A1
(es)
|
2017-03-31 |
2019-06-12 |
Takeda Pharmaceuticals Co |
Compuesto aromático agonista de gpr40
|
WO2018181847A1
(ja)
|
2017-03-31 |
2018-10-04 |
武田薬品工業株式会社 |
芳香環化合物
|
JOP20180040A1
(ar)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
مثبطات pd-1/pd-l1
|
WO2018196768A1
(zh)
|
2017-04-26 |
2018-11-01 |
南京圣和药业股份有限公司 |
作为pd-l1抑制剂的杂环类化合物
|
WO2019008156A1
(en)
|
2017-07-07 |
2019-01-10 |
Rijksuniversiteit Groningen |
INHIBITORS OF PROTEIN / PROTEIN INTERACTION PD-1 / PD-L1
|
EP3658522B1
(en)
|
2017-07-28 |
2021-12-22 |
ChemoCentryx, Inc. |
Immunomodulator compounds
|
KR20200056989A
(ko)
|
2017-08-08 |
2020-05-25 |
케모센트릭스, 인크. |
마크로사이클릭 면역조절제
|
WO2019034172A1
(zh)
|
2017-08-18 |
2019-02-21 |
上海轶诺药业有限公司 |
一种具有pd-l1抑制活性的化合物、其制备方法及用途
|
US20200216542A1
(en)
|
2017-09-20 |
2020-07-09 |
Chugai Seiyaku Kabushiki Kaisha |
Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
|
JP7257393B2
(ja)
|
2017-10-03 |
2023-04-13 |
ブリストル-マイヤーズ スクイブ カンパニー |
免疫調節剤
|
WO2019074241A1
(ko)
|
2017-10-11 |
2019-04-18 |
정원혁 |
페닐아세틸렌 유도체를 포함하는 pd-1과 pd-l1의 상호작용 억제제
|
CN109678796B
(zh)
|
2017-10-19 |
2023-01-10 |
上海长森药业有限公司 |
Pd-1/pd-l1小分子抑制剂及其制备方法和用途
|
AU2018398887B2
(en)
|
2017-12-29 |
2024-03-14 |
Guangzhou Maxinovel Pharmaceuticals Co., Ltd |
Aromatic vinyl or aromatic ethyl derivative, preparation method therefor, intermediate, pharmaceutical composition, and application
|
JP7062792B2
(ja)
|
2018-02-13 |
2022-05-06 |
ギリアード サイエンシーズ, インコーポレイテッド |
Pd-1/pd-l1阻害剤
|
WO2019165043A2
(en)
|
2018-02-22 |
2019-08-29 |
Chemocentryx, Inc. |
Indane-amines as pd-l1 antagonists
|
BR102019004480B1
(pt)
|
2018-03-08 |
2023-03-28 |
Dow Agrosciences Llc |
Picolinamidas como fungicidas
|
GB201803736D0
(en)
|
2018-03-08 |
2018-04-25 |
Syngenta Participations Ag |
Improvements in or relating to organic compounds
|
EP4056560A1
(en)
|
2018-03-08 |
2022-09-14 |
Incyte Corporation |
Aminopyrazine diol compounds as pi3k-y inhibitors
|
CN111788193B
(zh)
|
2018-03-13 |
2023-04-04 |
广东东阳光药业有限公司 |
Pd-1/pd-l1类小分子抑制剂及其在药物中的应用
|
AU2019234185A1
(en)
|
2018-03-13 |
2020-10-01 |
Jubilant Prodel LLC. |
Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation
|
CA3093851A1
(en)
|
2018-03-29 |
2019-10-03 |
Arbutus Biopharma Corporation |
Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same
|
AU2019245288C1
(en)
|
2018-03-30 |
2024-01-18 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
EP3774750A4
(en)
|
2018-04-03 |
2021-12-29 |
Betta Pharmaceuticals Co., Ltd |
Immunomodulators, compositions and methods thereof
|
WO2019204609A1
(en)
|
2018-04-19 |
2019-10-24 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
CA3099994A1
(en)
|
2018-05-11 |
2019-11-04 |
Incyte Corporation |
Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
|
CN112399874B
(zh)
|
2018-07-13 |
2024-03-22 |
吉利德科学公司 |
Pd-1/pd-l1抑制剂
|
CN112424185A
(zh)
|
2018-07-13 |
2021-02-26 |
广州丹康医药生物有限公司 |
含苯环的化合物、其制备方法及应用
|
KR102635333B1
(ko)
|
2018-10-24 |
2024-02-15 |
길리애드 사이언시즈, 인코포레이티드 |
Pd-1/pd-l1 억제제
|